Find Momelotinib manufacturers, exporters & distributors on PharmaCompass

Momelotinib

Momelotinib

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

1 NDC API

1 NDC API

DEVELOPMENTS

22 Drug(s) in Development

22 Drug(s) in Development

INTERMEDIATES

1 Suppliers

1 Suppliers

DIGITAL CONTENT

1 Data Compilations & Company Tracker #PharmaFlow, 27 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Cyt387, 1056634-68-4, Cyt-387, Cyt 387, N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide, Cyt 11387

Molecular Formula

C₂₃H₂₂N₆O₂

Molecular Weight

414.5 g/mol

InChI Key

ZVHNDZWQTBEVRY-UHFFFAOYSA-N

FDA UNII

6O01GMS00P

Momelotinib is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.

1 2D Structure

Momelotinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide

2.1.2 InChI

InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)

2.1.3 InChI Key

ZVHNDZWQTBEVRY-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N

2.2 Other Identifiers

2.2.1 UNII

6O01GMS00P

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Cyt 387

2. Cyt-387

3. Cyt387

4. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

2.3.2 Depositor-Supplied Synonyms

1. Cyt387

2. 1056634-68-4

3. Cyt-387

4. Cyt 387

5. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide

6. Cyt 11387

7. N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

8. Gs-0387

9. Momelotinib (cyt387)

10. Cyt-11387

11. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide

12. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

13. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide

14. 6o01gms00p

15. Chembl1078178

16. Cyt-0387

17. Cyt11387

18. Mfcd16038899

19. Lm-1149

20. N-(cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide

21. N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide

22. Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-

23. Momelotinib [usan]

24. Momelotinib [usan:inn]

25. Momelotinibum

26. Unii-6o01gms00p

27. Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-

28. C87

29. Momelotinib [inn]

30. Momelotinib (usan/inn)

31. Momelotinib [who-dd]

32. Mls006011154

33. Gtpl7791

34. Schembl2237234

35. Chebi:91407

36. Ex-a260

37. Dtxsid801026049

38. Hms3244k19

39. Hms3244k20

40. Hms3244l19

41. Hms3295i01

42. Hms3655d12

43. Hms3744c15

44. Bcp02328

45. Cyt387, Cyt11387

46. Cyt387,cyt 11387

47. Momelotinib (cyt387,cyt-387)

48. Bdbm50311017

49. Nsc767598

50. Nsc800800

51. S2219

52. Zinc43199890

53. Akos015904624

54. N-(cyanomethyl)-4-[2-[(4-morpholinophenyl)amino]-4-pyrimidinyl]benzamide

55. Bcp9000570

56. Ccg-264946

57. Cs-0053

58. Db11763

59. Nsc-767598

60. Nsc-800800

61. Sb14602

62. Ncgc00244257-01

63. Ncgc00244257-08

64. Ac-23162

65. As-19389

66. Hy-10961

67. Smr004702928

68. Sy060668

69. Ft-0755949

70. Sw219679-1

71. D10315

72. A857769

73. Q252602

74. J-001468

75. J-523159

76. Brd-k87737963-001-01-1

77. N-(cyanomethyl)-4-(2-(4-morpholinoanilino)pyrimidin-4-yl)benzamide

78. N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide

79. N-(cyanomethyl)-4-[2-[4-(4-morpholinyl)anilino]-4-pyrimidinyl]benzamide

80. N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide

81. Benzamide,n-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-

82. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide;cyt387

83. Cyt 11387, Cyt-387, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide

2.4 Create Date

2008-12-01

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₂N₆O₂
Molecular Weight	414.5 g/mol
XLogP3	2.6
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	6
Exact Mass	414.18042397 g/mol
Monoisotopic Mass	414.18042397 g/mol
Topological Polar Surface Area	103 Å²
Heavy Atom Count	31
Formal Charge	0
Complexity	615
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of myelofibrosis

Treatment of post-polycythaemia vera myelofibrosis, Treatment of polycythaemia vera, Treatment of post-essential thrombocythaemia myelofibrosis, Treatment of essential thrombocythaemia, Treatment of acute lymphoblastic leukaemia

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)